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Alzheimer’s disease (AD) is characterized by a progressive memory decline and numerous
pathological abnormalities, including amyloid β (Aβ) accumulation in the brain and synaptic
dysfunction. Here we wanted to study whether these brain changes were associated
with alteration in the population of monocyte subsets since accumulating evidence
supports the concept that the innate immune system plays a role in the etiology of
this disease. We then determined the immune profile together with expression of genes
encoding synaptic proteins and neurotrophins in APPSwe/PS1 mice and their age-matched
wild-type (WT) littermates. We found that the progressive cognitive decline and the
dramatic decrease in the expression of numerous synaptic markers and neurotrophins
correlated with a major defect in the subset of circulating inflammatory monocytes.
Indeed the number of CX CR1low high3 Ly6-C CCR2+Gr1+ monocytes remained essentially
similar between 5 weeks and 6 months of age in APPSwe/PS1 mice, while these cells
significantly increased in 6-month-old WT littermates. Of great interest is that the onset of
cognitive decline was closely associated with the accumulation of soluble Aβ, disruption of
synaptic activity, alteration in the BDNF system, and a defective production in the subset
of CX3CR1lowLy6-ChighCCR2+Gr1+ monocytes. However, these memory impairments can
be prevented or restored by boosting the monocytic production, using a short treatment
of macrophage colony-stimulating factor (M-CSF). In conclusion, low CCR2+ monocyte
production by the hematopoietic systemmay be a direct biomarker of the cognitive decline
in a context of AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
order affecting the elderly. AD begins as mild short-termmemory
deficits and culminates in total loss cognition and executive func-
tions. The two core pathological hallmarks are amyloid deposits
and neurofibrillary tangles (Selkoe, 2002). These senile plaques
appeared primarily in the cerebral cortex and hippocampus, leav-
ing the brainstem and cerebellum essentially unaffected. Amyloid
precursor protein (APP) is cleaved to produce beta-amyloid (Aβ)
peptides, namely Aβ1–40 and Aβ1–42. Aβ oligomerizes to form Aβ
oligomers, small aggregates of 2–12 peptides, and then aggregates
to form pro-fibrils and fibrils to generate the Aβ plaque (Lesné
et al., 2006; Haass and Selkoe, 2007). Although Aβ deposits were
for a long time thought to induce mnesic impairments, the cor-
relation between parenchymal amyloid deposition and cognitive
decline still remains controversial. Indeed, plaque density and Aβ
load do not necessarily correspond to the degree of dementia.
Accumulating evidence supports a detrimental role of soluble Aβ
in the brains of both AD patients (Lue et al., 1999; McLean et al.,
1999) and mouse models of AD (Lesné et al., 2006, 2008; Cheng
et al., 2007). Such intraneuronal and extracellular accumulation
of soluble Aβ oligomers may cause neuronal dysfunctions much
before than neurodegeneration (Haass and Selkoe, 2007).
It is believed that AD begins with subtle alterations in the
hippocampal synaptic activity prior to frank neuronal degener-
ation (Selkoe, 2002). Soluble Aβ may affect synaptic functions
since it abrogates synaptic plasticity and induces memory impair-
ments (Ma and Klann, 2011) and interferes with normal activity
and trafficking of several synaptic receptors (Ma and Klann,
2011). Moreover Aβ is able to modify the expression of genes crit-
ical for learning andmemory or neuroprotection in hippocampus
(Dickey et al., 2003).
In human and mouse AD brain, microglia are associated with
cerebral amyloid deposits (Dickson et al., 1988; Haga et al., 1989;
Malm et al., 2005; Stalder et al., 2005; Simard et al., 2006).
Microglia, the mononuclear phagocyte of the brain (Perry and
Gordon, 1988), react to Aβ and have the ability to phagocytose it
(Bolmont et al., 2008; Boissonneault et al., 2009; Mandrekar et al.,
2009; Lee et al., 2010; Liu et al., 2010). However, the progressive
Aβ accumulation together with the activation and recruitment
of microglia toward plaque formation suggests that the ability
of microglia to clear Aβ decreases with age and during AD pro-
gression (Hickman et al., 2008). Recent studies demonstrate that
several subsets of microglia exist and can have different roles and
properties (Naert and Rivest, 2011b). Microglia are replenished
by division of resident cells and by recruitment of peripheral
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monocytes during neuropathological conditions (Simard and
Rivest, 2004; Simard et al., 2006; Soulet and Rivest, 2008).
Immunocompetent bone marrow-derived microglia (BMDM)
have been shown to restrict amyloid pathology and prevent the
cognitive decline in mouse models of AD (Simard and Rivest,
2006; Town et al., 2008; Mildner et al., 2011; Naert and Rivest,
2012). These data support the concept that microglia precursor
recruitment from circulating monocytes is a natural protective
mechanism against Aβ accumulation and cognitive decline.
Monocytes population is divided into three subsets in
human and two subsets in mice, namely inflammatory sub-
set CX3CR1lowLy6-ChighGr1+CCR2+ and the patrolling mono-
cyte CX3CR1highLy6-ClowGr1−CCR2− (Geissmann et al., 2003;
Auffray et al., 2009). Both subsets might be able of infiltrating
in inflamed brain, with predominantly Ly6-Chigh cells (Saederup
et al., 2010). However, CX3CR1lowLy6-ChighGr1+CCR2+ sub-
set is believed to be largely responsible of the blood-derived
microglia during pathological conditions (Mildner et al., 2007;
Getts et al., 2008; Naert and Rivest, 2012). The chemokine CCL2
is the main CCR2 ligand and is upregulated in brains of AD
patients andmousemodels of AD (Ishizuka et al., 1997; Grammas
and Ovase, 2001; Simard et al., 2006; El Khoury et al., 2007;
Naert and Rivest, 2011a), suggesting the preferential recruit-
ment of CCR2+ monocytes. Recently we have shown that CCR2
deficiency in APPSwe/PS1 mice aggravated mnesic impairments
and enhanced Aβ pathology (Naert and Rivest, 2011a). In addi-
tion, CCR2 deficiency specifically in bone marrow cells also
enhanced AD physiopathology in APPSwe/PS1 mice (Mildner
et al., 2011; Naert and Rivest, 2012) and these effects were pre-
vented by the transplantation of competent CCR2 hematopoietic
stem cells (Naert and Rivest, 2012). Of great interest are the data
that CCR2 gene delivery in bone marrow cells rescued mem-
ory impairments of non-irradiated APPSwe/PS1 mice, suggesting
a defect in the CCR2 system during AD (Naert and Rivest,
2012). These data underline the possibility that hematopoietic
system is defective in AD subjects and in a context of APP gene
overexpression.
The aim of this study was therefore to compare the immune
profile together with synaptic dysfunction and soluble Aβ accu-
mulation in APPSwe/PS1 mice before and after the onset of
mnesic impairments. We took advantage of this mouse model
since each mother delivery generates around 50% double trans-
genic and 50% wild-type (WT) allowing a perfect match between
APPSwe/PS1 mice and WT littermates of the same gender. We
used only male for this study to avoid the possible influence
of the ovulatory cycle and variations in circulating levels of sex
steroids on the immune system. Compared to their WT lit-
termates 6-month-old APPSwe/PS1 mice exhibit a clear defect
in the production inflammatory monocytes and this correlates
with mnesic impairments, reduction in synaptic markers, and
accumulation of soluble Aβ.
MATERIALS ANDMETHODS
ANIMALS
We used adult male C57BL/6 mice (WT), CCR2−/− (B6.129S4-
Ccr2tm1Ifc/J) and APP transgenic mice (APPSwe/PS1) harbor-
ing the chimeric mouse/human β-amyloid precursor protein
(APP695swe) and the human presenilin I (A246E variant) under
the control of independent mouse prion protein promoter ele-
ments [B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J]. All themice
were originally purchased from the Jackson Laboratory andmain-
tained in a pure C57BL/6J background. APPSwe/PS1 were bred
with the CCR2−/− mouse strain for ≥3 generations to gener-
ate APPSwe/PS1/CCR2−/− triple transgenic animals. All newborn
pups were genotyped as described previously (Simard and Rivest,
2006) and double transgenic andWT littermates weremaintained
in the same environment Mice were housed 3–5 per cage and
acclimated to standard laboratory conditions (12-h light, 12-h
dark cycle; lights on at 07:00 and off at 19:00) with free access
to mouse chow and water. Animal breeding and experiments
were conducted according to Canadian Council on Animal Care
guidelines, as administered by the Laval University Animal Care
Committee.
BEHAVIORAL ANALYSES: WATER T-MAZE
Mice were tested during the “light-on” phase of the day.
Behavioral experimenter was blind to the genetic and treatment
status of animals. To assess hippocampal-dependent spatial learn-
ing and memory, mice were trained in the water T-maze task.
In this paradigm, we evaluate the mouse’s ability to remember
the spatial location of submerged platform. The T-maze appara-
tus (stem length, 64 cm; arms length, 30 cm; width, 12 cm; wall
height, 16 cm) was made of clear fiberglass and filled with water
(23 ± 1◦C) at a height of 12 cm. A platform (11 × 11 cm) was
placed at the end of the target arm andwas submerged 1 cm below
the surface. The acquisition phase allows to evaluate animals for
left-right spatial learning. During the first two trials, platforms
were placed on each arm of the maze to test the spontaneous
turning preference of the mouse. After these two trials, the least
chosen arm was reinforced by the escape platform. The mice were
placed in the stem of the T-maze and were left to choose swim-
ming either left or right until they found the submerged platform
and escaped to it for a maximum of 60 s. After reaching the plat-
form, the mice remained on it for 20 s and were then immediately
placed back into the maze. If the animals did not find the plat-
form within this limit, they were gently guided onto it. Repeated
trials were presented on the same day up to a maximum of 48 tri-
als. A rest period of at least 10–15min intervened between each
block of 10 trials. A mouse was considered to have learned the
task when it made no errors in a block of five consecutive tri-
als. The reversal learning phase was then conducted 48 h later.
During this phase, the same protocol was repeated, except that
mice were trained to find the escape platform on the side opposite
to where they had learned in the acquisition phase. The number of
trials to reach the criterion (5/5 correct choices made on consec-
utive trials) was measured as well as the latency to find the escape
platform.
TISSUE ANALYSES
Mice were anesthetized under isofluorane. For first group of mice
used for behavioral analysis, brains were rapidly removed from
the skulls and placed for 2–4 days in 4% paraformaldehyde (PFA),
pH 9.5 at 4◦C, and then placed in a PFA solution containing
10% (w/v) sucrose overnight at 4◦C. The frozen brains were
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mounted on a microtome (Reichert-Jung) and cut into 25-μm
coronal sections. The slices were collected in cold cryoprotec-
tant solution (0.05M sodium phosphate buffer, pH 7.3, 30%
ethylene glycol, and 20% glycerol) and stored at −20◦C until
performing immunocytochemistry or in situ hybridization his-
tochemistry. A second group of mice was used for hippocampus
analysis. Hippocampus were rapidly removed from the brain,
frozen in liquid nitrogen, and stored at −80◦C for RNA and
protein analysis.
In situ hybridization and immunohistochemistry
Every 12th section of brain slices, starting from the end of
the olfactory bulb to the end of the cerebral cortex, was
mounted on Colorfrost/Plus microscope slides (Fisher Scientific)
for WT and APPSwe/PS1 mice, from 3 to 12 months of
age, (n = 5–12 per group). In situ hybridization for the his-
tochemical localization of brain-derived neurotrophic factor
(BDNF), early-growth response protein 1 (Egr1), activity-
regulated cytoskeleton-associated gene (Arc), two subunits of the
N-methyl-D-aspartate-type (NMDA) glutamate receptor, NR2A
and NR2B, was performed using 35S-labeled cRNA probes.
Plasmids were linearized, sense and antisense cRNA probes were
synthesized with the appropriate RNA polymerase, as described
in Table 1. Riboprobe synthesis and preparation and in situ
hybridization were performed according to a previously described
protocol (Laflamme et al., 1999; Laflamme and Rivest, 2001;
Nadeau and Rivest, 2000; Naert et al., 2009).
All images were captured using a Nikon Eclipse 80i micro-
scope equipped with a digital camera (QImaging), processed to
enhance contrast and sharpness using Adobe Photoshop 7 (Adobe
Systems), and then assembled using Adobe Illustrator (Adobe
Systems). The images depicted by the different panels are rep-
resentative of the signal detected on the slides for each group
of mice.
Stereological analysis
An observer who was blind to the treatment status of the
material did all quantitative histological analyses. To count
Table 1 | Plasmids and enzymes used for the synthesis of the cRNA
probes.
Plasmid Vector Insert Antisense
probe
Sense
probe
Source
Mouse
Arc
PCR II
Topo
869 bp EcoR I/Sp6 Hind
III/T7
Cloned by PCR
Mouse
BDNF
PCR II
Topo
342 bp Xho I/Sp6 BamH
I/T7
Dr. D. Levesque,
Laval University,
Québec, QC, Canada
Mouse
EGR1
PCR II
Topo
965 bp Xba I/Sp6 BamH
I/T7
Cloned by PCR
Mouse
NR2A
PCR II
Topo
1017 bp BamH I/SP6 Xho
I/T7
Cloned by PCR
Mouse
NR2B
PCR II
Topo
755 bp BamH I/T7 Xba
I/Sp6
Cloned by PCR
Aβ plaques, sections of 3- and 6-month-old APPSwe/PS1 mice
(n = 6–15 per group) were immunostained for Aβ protein (poly-
clonal mouse anti-Aβ 6E10;Covariance) with 4′, 6′-diamidino-2-
phenylindole, as previously reported (Simard et al., 2006; Richard
et al., 2008). Four sections were chosen for hippocampus at
−1.70, −1.94, −2.46, and −2.92mm from the bregma accord-
ing to a stereotaxic atlas (Paxinos and Franklin, 2nd edition).
Unbiased stereological analysis was performed as described pre-
viously (Simard et al., 2006; Richard et al., 2008; Boissonneault
et al., 2009). Briefly, the contours of the hippocampus areas were
traced as virtual overlays on the steamed images and areas were
calculated. The area occupied by all Aβ-labeled plaques was
determined as previously described (Naert and Rivest, 2011a).
Protein and RNA extraction
Proteins from hippocampus of 3- and 6-month-old WT and
APPSwe/PS1 mice were extracted using a modified version of
the procedure published by Lesné et al. (2006). All manipula-
tions were done on ice to minimize protein degradation. One
hippocampus was placed in a 1-ml syringe with a 20 G nee-
dle. 250μl of buffer A (50mM Tris-HCl pH 7.6, 0.01% NP-40,
150mM NaCl, 2mM EDTA, 0.1% SDS, 1mM phenylmethylsul-
fonyl fluoride (PMSF), protease inhibitor cocktail) were added
and 10-up-and-down strokes were made to homogenize the tis-
sue. The mixture was then separated in two tubes one for protein
extraction and the other for RNA extraction.
The tube for protein was centrifuged for 5min at 3000 rpm
at 4◦C. The supernatant (extracellular proteins enriched frac-
tion) was collected and frozen at –80◦C. The insoluble pellet
was suspended in 250μl TNT-buffer (Buffer B; 50mM Tris-
HCl pH 7.6, 150mM NaCl, 0.1% Triton X-100, 1mM PMSF,
protease inhibitor cocktail), followed by a 90min centrifugation
at 13,000 rpm at 4◦C. The supernatant (cytoplasmic proteins
enriched fraction) was then collected and frozen at −80◦C. The
pellet was suspended in 250μl buffer C (50mM Tris-HCl pH 7.4,
150mM NaCl, 0.5% Triton X-100, 1mM EGTA, 3% SDS, 1%
deoxycholate, 1mM PMSF, protease inhibitor cocktail) and incu-
bated at 4◦C, 50 rpm, for 1 h. The samples were centrifuged for
90min at 13,000 rpm and 4◦C and the supernatant (membrane
proteins enriched fraction) was collected and frozen at −80◦C.
Protein concentration of each fraction was determined using the
Quantipro BCA assay kit (Sigma) according to the manufacturer
protocol.
Total RNA was isolated from hippocampus mixture for 3- and
6-month-old WT and APPSwe/PS1 mice using TRIzol reagent
method according to the manufacturer’s protocol (Sigma) and
then digested with deoxyribonuclease to remove any contaminat-
ing genomic DNA (Turbo DNA-free from Ambion, Austin, TX).
Quantitative RT-PCR analysis
RNA quantity and quality was assessed using an Agilent
Technologies 2100 bioanalyzer and RNA 6000 Nano LabChip kit
(Agilent, Mountain View, CA). Complementary DNA (cDNA)
was generated from 40 ng of total RNA using a random primer
hexamer following the protocol for Superscript II (Invitrogen,
Carlsbad, CA). Equal amounts of cDNAwere run in triplicate and
amplified in a 15μl reaction containing 7.5μl of 2× Universal
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PCR Master Mix (Applied Biosystems, Foster City, CA), 10 nM
of Z-tailed forward primer, 100 nM of reverse primer, 250 nM of
Amplifluor Uniprimer probe (Chemicon, Temecula, California),
and 1μl of cDNA target. Moreover, no-template controls were
used as recommended. The mixture was incubated at 50◦C for
2min, at 95◦C for 4min, and then cycled at 95◦C for 15 s and
at 55◦C for 30 s, 55 times using the Applied Biosystems Prism
7900 Sequence Detector. Amplification efficiencies were validated
and normalized to ribosomal 18S gene and quantity of target gene
was calculated according to a standard curve. Primers sequences
were designed using Primer Express 2.0 (Applied Biosystems)
and are described in Table 2. Amplicons were detected using the
Amplifluor UniPrimer system, in which forward primers used
contained a 5′ Z sequence: ACTGAACCTGACCGTACA.
Detection of total Aβ levels by Western blot
For total Aβ detection, 10–20μg of extracellular, cytoplasmic,
and membrane protein fractions of hippocampus were sepa-
rated on a precast 4–20% polyacrylamide Tris-Glycine eXtended
(TGX) gel (Bio-Rad). Separated proteins were then transferred
onto polyvinylidene fluoride (PVDF) membranes (PerkinElmer
Life and Analytical Sciences) and detected by Western blot-
ting. Blots were probed with a mouse anti-amyloid beta protein
monoclonal antibody clone 6E10 (1:1500, Covariance) in 1M
Tris-HCl, pH 8.0, 5M NaCl, 5% skim milk, and 0.05% Tween
20. Blots were visualized using anti-mouse secondary antibody
tagged with horseradish peroxidase (1:1000; Jackson Immuno-
Research) and enhanced chemiluminescence (PerkinElmer Life
and Analytical Sciences). Membranes were stripped in 25mM
glycine-HCl, pH 2.0, containing 1% SDS to allow β-actin
revelation using first a mouse β-actin antibody (MAB1501,
1:5000; Millipore Bioscience Research Reagents) and then a goat
anti-mouse peroxidase conjugated secondary antibody (1:1000;
Jackson ImmunoResearch).
Quantification was done by determining integrative density
of the bands using a gel imaging system (scanner Agfa Arcus II;
NIH Image J software version 1.32j) and background values were
removed. Optical values were normalized according to the actin
loading control. Results are expressed as mean ± SEM.
FACS ANALYSES
Analysis of circulating monocytes
Fluorescence-activated cell sorting (FACS) analysis was per-
formed on red blood cell-lysed blood of 5-week- and 6-month-
old WT and APPSwe/PS1 mice. Blood of CCR2−/− mice was
used as negative control of CCR2 staining. To analyze the pop-
ulation of monocytes, anti-coagulated whole blood was taken
from the facial vein and quickly suspended and cells were
washed in Dulbecco’s PBS (DPBS) + 4% fetal bovine serum
(FBS). Cells, suspended in DPBS + 2% FBS, were first incu-
bated on ice for 15min with purified rat anti-mouse CD16/CD32
(Mouse BD Fc Bloc, BD Bioscience). The mix was then incu-
bated on ice with Phycoerythrin (PE)-conjugated CD45 antibody
(BD Bioscience), PE-Cy7™-conjugated CD11b antibody (eBio-
science), allophycocyanin (APC)-conjugated CD115 antibody
(eBioscience), FITC-conjugated Ly6-C antibody (BD Bioscience),
and PerCP-Cy5.5™-conjugated Gr1 antibody (Cedarlane) for
35min. Cells were washed again in DPBS + 2% FBS. Red blood
Table 2 | Primers sequence for real time PCR.
Gene (mus musculus) mRNA RefSeq number Primer sequence 5′ →3′ (Z-tail)
Arc NM_018790 Fwd ACTGAACCTGACCGTACAAGGGTGAACCACTCGACCAGT
Rev TCTGGTACAGGTCCCGCTTG
Bdnf NM_001048142 Fwd CTGACGACGACATCACTGGC
Rev ACTGAACCTGACCGTACACAGCTCTTCGATGACGTGCTC
Dlg4 (PSD95) NM_001109752 Fwd ATTCCCAGCAAACGGCG
Rev ACTGAACCTGACCGTACAGGCCTTTAACCTTGACCACTCTC
Egr1 NM_007913 Fwd ACTGAACCTGACCGTACAAGCACCTGACCACAGAGTCCTT
Rev CCTTCTCATTATTCAGAGCGATGTC
Grin2a (NR2A) NM_008170 Fwd ACTGAACCTGACCGTACATAGCAGGCCCTCTCGTAGCA
Rev TCCAGTAGCCTTTCCCTGTCC
Grin2b (NR2B) NM_008171 Fwd TATGTGGACCAGGTTTCCGG
Rev ACTGAACCTGACCGTACAATTAGGTCTCTGGAACTTCTTGTCACT
Gria1 (AMPA 1) NM_008165 Fwd ACTGAACCTGACCGTACATGCCAATTTCCCCAACAATATC
Rev TGTTGGTTTGGAAATAATCCCC
h18S/m18S M10098 Fwd ACTGAACCTGACCGTACACGGTACAGTGAAACTGCGAATG
Rev CCAAAGGAACCATAACTGATTTAATGA
Ntrk2 (TrkB full length) NM_008745 Fwd GTGGTGTCATTAGTAGGTTCTTTGTTTT
Rev ACTGAACCTGACCGTACAGAGTTTGGGTCTTTGCTGCC
Ntrk2 (TrkB T1) NM_001025074 Fwd GACCTCAACAAGTTCCTTAGGGC
Rev ACTGAACCTGACCGTACATGCCATCAGCACTGCGTC
Ntrk2 (TrkB T2) BC052014 Fwd CCCAGTTGGTGGTGTGTGG
Rev ACTGAACCTGACCGTACAGGACAAACAGACATGGATGAGACT
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cells were lysed with hemolysin according to the manufacturer’s
protocol (Beckman Coulter, Mervue, Galway, Ireland) and cells
were washed with DPBS and re-suspended in equal volumes
of DPBS. For CCR2 detection, washed cells were first incu-
bated on ice with monoclonal antibody MC-21 (anti-CCR2)
for 60min (Mack et al., 2001). After washing, cells were incu-
bated for 60min on ice with a biotin-labeled anti-rat poly-
clonal antibody (BD Bioscience). Cells were washed again and
incubated with purified rat anti-mouse CD16/CD32 on ice
for 15min, before adding PerCP™-labeled streptavidin (BD
Bioscience) and the combination of directly conjugated anti-
bodies as described previously (Mack et al., 2001). Cells were
analyzed using a two-lasers and six color FACS Canto II
flow cytometer and data acquisition was done with BD Facs
Diva software (version 6.1.2, BD Biosciences, Mississauga, ON,
Canada). Cells were then sorted according to the different fluo-
rescent antibodies. Results were analyzed using Flow Jo software
(Tristar).
Determination of Ly6-Chigh monocytes in the bone marrow
Male WT and APPSwe/PS1 mice, 6–6.5 months of age, were
used to determine the frequency of inflammatory monocytes
in the bone marrow. The cells were aseptically harvested for
each mice by flushing the two tibias and femurs with DPBS
containing 2% FBS. Cell samples were combined for each
mouse, filtered through a 40-μm nylon mesh, centrifuged, and
were washed with DPBS and re-suspended in equal volumes
of DPBS + 2% FBS. Cells were first incubated on ice for
15min with purified rat anti-mouse CD16/CD32 (Mouse BD
Fc Bloc, BD Bioscience). The mix was then incubated on ice
with PE-conjugated CD11b antibody (BD Bioscience), horizon
V500-conjugated CD45 antibody (BD Bioscience), and Pacific
blue-conjugated Ly6-C antibody (Biolegend) for 35min. Cells
were analyzed using a two-lasers and six color FACS Canto II
flow cytometer and data acquisition was done with BD Facs
Diva software (version 6.1.2, BD Biosciences, Mississauga, ON,
Canada). Cells were then sorted according to the different fluo-
rescent antibodies. Results were analyzed using Flow Jo software
(Tristar).
MACROPHAGE COLONY-STIMULATING FACTOR (M-CSF) TREATMENT
WT and APPSwe/PS1 mice received daily an ip injection of murine
M-CSF (40μg/Kg) (R&D Systems) during 4 days at the age of 3 or
6 months and were tested 3 months later in the T-maze paradigm.
The experimental procedure for these two protocols is depicted
in the Figure 8. The first experiment consisted to treat animals
before the occurrence of mnesic impairments and Aβ pathol-
ogy (Figure 8A), whereas in the second experiment animals were
administered after the occurrence of cognitive decline, synaptic
disruption and Aβ pathology (Figure 8D).
To determine the potential role of CCR2 in mediating the
effects of M-CSF on monocytes, WT, CCR2, APPSwe/PS1, and
APPSwe/PS1/CCR2−/− mice received daily ip injections of the
cytokine (40μg/Kg) during 4 days at the age of 3.5–4 months.
Twenty-four hours after the fourth injection, the whole blood
was taken from the facial vein to perform FACS analysis.
As previously explained, PE-Cy7™-conjugated CD11b antibody
(eBioscience), PE-conjugated CD45 antibody (BD Bioscience),
and APC-conjugated CD115 antibody (eBioscience) were used to
determine the population of monocytes.
STATISTICAL ANALYSES
Results are expressed as the mean ± SEM. Statistical analysis was
performed by one- or two-way analysis of variance (ANOVA),
followed by the appropriate test procedure, using Bonferroni or
Tamhane’s tests as post-hoc comparisons (SPSS software). Data
were analyzed using standard two-tailed unpaired t-test’s for the
comparison between two groups. Correlations were estimated by
linear regression analysis and the Spearman’s correlation coeffi-
cient (GraphPad Software Inc.) with p- and r-values and 95%
confidence intervals included in the graph. A p-value <0.05 was
considered statistically significant.
RESULTS
THE OCCURRENCE OF MNESIC IMPAIRMENTS DOES NOT CORRELATE
WITH Aβ DEPOSITS
Coronal brain sections of WT and APPSwe/PS1 mice at 3 and
6 months of age were immunostained with the 6E10 anti-
body specific for the 1–16 fragment of the human Aβ protein.
Plaques surface were determined by stereological analysis in hip-
pocampus. Aβ deposits are scarce in 3-month-old APPSwe/PS1
mice (Figures 1A–B). Indeed, insoluble Aβ begins to accu-
mulate at 6 months of age (Figures 1A–B). Density and area
occupied by Aβ deposits are robustly increased in hippocam-
pus at 6 months of age (Figures 1A–B). These results seem
to support a positive correlation between the onset of plaque
formation and cognitive impairment. Therefore, we investigated
if mnesic deficit correlated positively with Aβ load at the age of
6 months. We determined the correlation between spatial mem-
ory decline (water T-maze test) and the percentage area occupied
by plaque in hippocampus in each 6-month-old APPSwe/PS1
mice. Surprisingly no correlation was observed for both struc-
tures (Figure 1C).
As mnesic impairments occurred at 6 months of age (Naert
and Rivest, 2011a), we precisely compared the hippocampal level
of soluble Aβ oligomers in APPSwe/PS1 mice at 3 and 6 months
of age. Using a modified version of the Lesné’s protocol (Lesné
et al., 2006), we performed western blotting for extracellular-
and intracellular-enriched proteins. The different Aβ oligomers
were revealed using the 6E10 antibody. In the extracellular-
enriched fraction, 6-month-old APPSwe/PS1 mice exhibited an
important increase of low-n oligomers. Indeed levels of 8-, 6-,
and 1-mer were significantly increased (Figures 1D–E). In the
intracellular fraction, soluble oligomers (12-, 6-, and 3 -mer)
were augmented (Figures 1F–G). Therefore, a robust accumu-
lation of soluble Aβ occurred in hippocampus of 6-month-old
APPSwe/PS1 mice.
APPswe/PS1 MICE AT THE AGE OF 6 MONTHS EXHIBITED A DECREASE
IN TRANSCRIPT LEVEL OF BDNF AND ITS RECEPTORS IN
HIPPOCAMPUS
As mnesic impairment appeared at the age of 6 months in
APPSwe/PS1 mice, we compared the BDNF transcript levels in
WT and APPSwe/PS1 mice at 3 and 6 months of age. WT and
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FIGURE 1 | Six-month-old APPSwe/PS1 mice had higher level of Aβ
soluble oligomers in the hippocampus. Anti-Aβ immunoreactivity is
depicted in hippocampus of APPSwe/PS1 at 3 and 6 months of age (A).
A detailed analysis of plaque quantification was performed to determine
the percentage area occupied by plaques (B) of 3- and 6-month-old
APPSwe/PS1. Aβ load was strongly increased at 6 months age in
hippocampus. A correlation’s test revealed no significant correlation
between spatial memory decline (water T-maze test) and the percentage
area occupied by plaques at the age of mnesic deficit occurrence
(6 months) (C). Therefore, the hippocampus level of soluble Aβ was
analyzed by western blotting for extracellular and intracellular-associated
proteins of 3- and 6-month-old APPSwe/PS1 mice. The intensity of each
band was quantified by densitometric analysis and normalized per β-actin
values. Aβ species ratios (Aβ/β-actin) are represented and increased
levels of Aβ soluble oligomers were observed at 6 months of age in
extracellular (D–E) and intracellular (F–G). Results are expressed as the
Mean ± SEM; n = 6–7; Student’s t-test; ∗p < 0.05, ∗∗p < 0.01 and
∗∗∗p < 0.001. ∗ vs. APPSwe/PS1 at 3 months of age. Magnification 4×.
Correlation test was performed using the Spearman’s correlation
coefficient.
APPSwe/PS1 mice exhibited similar expression of BDNF mRNA
in hippocampus at 3 months of age, as revealed by hybridization
in situ (Figure 2A) and quantitative RT-PCR analysis (Figure 2B).
On the other hand, 6-month-old APPSwe/PS1 mice had lower
BDNF mRNA levels in hippocampus, a 41% reduction was high-
lighted by quantitative RT-PCR analysis (Figure 2B). BDNF activ-
ity is dependent on TrkB and its downstream targets and levels of
the different isoforms of TrkB—TrkB full length (TrkB.FL), TrkB
T1, and TrkB T2—were assessed by quantitative RT-PCR analy-
sis in hippocampus. WT and APPSwe/PS1 mice expressed similar
TrkB.FL, TrkB T1, and TrkB T2 mRNA levels at 3 months of
age (Figures 2C–E), whereas these transcript levels were signifi-
cantly reduced by 27, 29, and 35%, respectively, in 6-month-old
APPSwe/PS1 mice (Figures 2C–E). These data suggest that the
BDNF system is affected in the in hippocampus of 6-month-old
APPSwe/PS1 mice.
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FIGURE 2 | Expression of BDNF and its receptors decreased in
hippocampus when mnesic deficits begin in APPSwe/PS1 mice.
Representative dark-field photomicrographs of in situ hybridization
showed the hippocampal expression of BDNF mRNA (A) in the brain
of 3- and 6-month-old WT and APPSwe/PS1 mice. For hippocampus,
mRNA levels of BDNF and its receptors—TrkB.FL, TrkB.T1, and
TrkB.T2—were determined by real-time qPCR and normalized relative to
the level of S18 mRNA detected in each sample. At 3 months of age,
APPSwe/PS1 mice exhibited similar mRNA levels of BDNF (A and B)
and its receptors, TrkB.FL (C), TrkB.T1 (D), and TrkB.T2 (E). In
contrast, all transcripts were significantly decreased in 6 month-old
APPSwe/PS1 mice compare to WT littermates (B–E). Results are
expressed as the Mean ± SEM; n = 5–9; Student’s t-test; ∗∗p < 0.01
vs. WT at the same age.
DECREASED EXPRESSION OF GENES ENCODING SYNAPTIC PROTEINS
THAT ARE CRITICAL FOR MEMORY AND LEARNING IN THE
HIPPOCAMPUS OF 6-MONTH-OLD APPswe/PS1 MICE
Expression of pre- and post-synaptic genes was assessed in hip-
pocampus by in situ hybridization and RT-PCR. We performed
in situ hybridization for Egr1, Arc, NMDA-R1 (NR2A), and -R2
(NR2B) transcripts in hippocampus of 3- and 6-month-old
WT and APPSwe/PS1 mice (Figure 3). At 3 months of age,
WT and APPSwe/PS1 mice exhibited similar signal for all tran-
scripts, whereas a decreased signal for Egr1, Arc, NR2A, and
NR2B mRNA was observed in the hippocampus of 6-month-old
APPSwe/PS1 mice (Figure 3). These results were confirmed using
RT-PCR analysis (Figure 4). Similar expression levels of these
transcripts were quantified in the hippocampus at 3 months of
age. However, Egr1, Arc, NR2A and NR2B, AMPA1, and PSD95
mRNA levels were significantly lower by 48, 47, 29, 27, 21, and
22%, respectively, in APPSwe/PS1 mice then their WT littermates
(Figure 4). These data highlight a defect in synaptic markers in
hippocampus of 6-month-old APPSwe/PS1 mice.
FREQUENCY OF LY6-ChighGR1+CCR2+ MONOCYTES IS SIGNIFICANTLY
REDUCED IN THE BLOODSTREAM AND THE BONE MARROW OF
6-MONTH-OLD APPswe/PS1 MICE
To assess whether monocytes were affected in a context of AD
and whether the occurrence of memory deficit may be linked
with impairment of the innate immune system, we determined
the frequency of monocytes in WT and APPSwe/PS1 mice before
(5 weeks of age) and at the beginning of the mnesic deficit
(6months of age). Leukocytes were labeled with CD45 andmono-
cytes were distinguished using CD11b and CD115 (CSF1/MCSF
receptor). At 5 weeks WT and APPSwe/PS1 mice exhibited
similar frequency of CD45+CD11b+CD115+ cells (Figures 5A
and C) and this monocyte number significantly increased in
6-month-old WT mice as depicted in the Figure 5C. Such a phe-
nomenon has previously been described (Boggs et al., 1986).
Of great interest is that monocyte frequency did not increase in
6-month-old APPSwe/PS1 mice and their circulating monocyte
number remained at the level of the young 5 week-old animals
(Figures 5A–C).
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FIGURE 3 | Egr1, Arc, NR2A, and NR2B transcript levels in
APPSwe/PS1 mice. Expression of Egr1, Arc, PSD95, AMPA1, NR2A, and
NR2B mRNA were determined by in situ hybridization. Three-month-old
WT and APPSwe/PS1 mice had similar mRNA levels of Egr1
(A), Arc (B), NR2A (C), and NR2B (D). In contrast, intensity of transcript
signal for Egr1 (A), Arc (B), NR2A (C), and NR2B (D) was lower in the
brain of APPSwe/PS1 mice than WT mice at 6 months of age.
Magnification 4×.
We then distinguished between the inflammatory subset
CX3CR1lowLy6-ChighGr1+CCR2+ and the patrolling monocyte
CX3CR1highLy6-ClowGr1−CCR2− by the expression of Gr1
(Figure 6). At 5 weeks of age, WT and APPSwe/PS1 mice exhib-
ited similar frequency of each subset (Figures 6A–D). The ratio
of Gr1+ and Gr1− monocyte is ∼60% and ∼40%, respec-
tively, in both group of mice (Figures 6A–D). At 6 months
of age the frequency of Gr1− monocytes was similar between
WT and APPSwe/PS1 mice (Figures 6B and D), but the pro-
portion of Gr1+ is reduced by almost 3 fold in 6-month-old
APPSwe/PS1 mice compared to their WT littermates (Figures 6A
and C). This group of WT mice had ∼70% of Gr1+ and
∼30% Gr1− monocyte, which is 2 fold more Gr1+ subset
than their APPSwe/PS1 progeny (Figures 6C and D). To con-
firm these results we used Ly6-C and CCR2 to further dis-
tinguish between the different subsets of monocytes. Blood
of CCR2-deficient mice was used as negative control for the
CCR2 antibody used in this study (data not shown). According
to the previous observation, we found a marked decrease
of Ly6-ChighCCR2+ monocytes in 6-month-old APPSwe/PS1
mice (Figures 6G–H), while Ly6-Cint and Ly6-Clow monocytes
remained similar in WT and APPSwe/PS1 mice at the same age
(data not shown).
To explain the defect in circulating Ly6-Chigh monocytes, we
assessed the frequency of this monocyte subset in the bone
marrow of 6-month-old APPSwe/PS1 mice. Using the common
leukocyte antigen CD45, we found a similar frequency and num-
ber of CD45+ cells in both WT and APPSwe/PS1 groups of mice
at 6 months of age (Figure 7A). CD11b and Ly6-C were con-
sequently used to identify the inflammatory monocyte subset
among these CD45+ cells and APPSwe/PS1 mice had significantly
less Ly6-Chigh monocytes in their bone marrows than WT lit-
termates (Figure 7B). This interesting result suggests strongly
that the production of Ly6-Chigh monocytes is decreased in the
bone marrow of 6-month-old APPSwe/PS1 mice. There is con-
sequently a clear defect of the hematopoietic system to produce
Ly6-ChighCCR2+ monocytes in 6-month-old APPSwe/PS1 mice
and this correlates with the beginning of the cognitive decline of
this mouse model of AD.
A SHORT MACROPHAGE COLONY-STIMULATING FACTOR (M-CSF)
TREATMENT INCREASES MONOCYTE FREQUENCY IN APPswe/PS1
MICE AND RESCUES THEIR COGNITIVE IMPAIRMENT
To assess whether defect in the population of monocytes is due
to their inability to differentiate properly and is a non-reversible
mechanism, we assessed the effect of the main hematopoietic
cytokine involved in monocytopoeisis, M-CSF, in APPSwe/PS1
mice. A short treatment with M-CSF (once/day, during 4 days)
was administered in APPSwe/PS1 mice before (at 3 months)
and after the occurrence of cognitive decline (at 6 months).
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FIGURE 4 | Occurrence of mnesic deficits correlate with decreased
mRNA levels of synaptic markers in hippocampus of APPSwe/PS1 mice.
Real-time qPCR was used to quantify Egr1, Arc, PSD95, AMPA1, NR2A, and
NR2B mRNA levels in the hippocampus. The values were normalized relative
to the level of S18 mRNA detected in each sample. 3-month-old WT and
APPSwe/PS1 mice had similar mRNA levels of Egr1 (A), Arc (B), PSD95 (C),
AMPA1 (D), NR2A (E), and NR2B (F). In contrast, all transcripts were
significantly decreased in APPSwe/PS1 mice at 6 months of age when mnesic
deficits begin. Results are expressed as the Mean ± SEM; n = 5–9;
Student’s t-test; ∗p < 0.05 and ∗∗p < 0.01 vs. WT at the same age.
Spatial memory of these mice was assessed 3 months later
using the water T-maze test (Figures 8A and D). M-CSF was
able to prevent the apparition of memory impairment, which
occurred normally at 6 months, as revealed by the number of
trials (10.4 ± 1.4 vs. 17.4 ± 1.7 for APPSwe/PS1 mice; p < 0.05)
(Figures 8A–C). M-CSF did also restore mnesic capacity—M-
CSF-treated APPSwe/PS1 mice at 9 months of age exhibited a
significant decrease of the number of trials (9.2 ± 1.9 vs. 21.4 ±
1.1 for APPSwe/PS1 mice; p < 0.001) (Figures 8D–F).
To determine whether M-CSF had the same effect on mono-
cytic commitment in WT and APPSwe/PS1 mice, we performed
FACS analysis on blood cells 24 h after the fourth injection of M-
CSF (40μg/Kg/day). Such a treatment increased the number of
monocytes (CD11b+CD115+) within the population of CD45+
cells (Figure 9). M-CSF caused a similar increase of monocyte
frequency in APPSwe/PS1 mice (Figure 9). This effect of M-CSF
was dependent on CCR2, because the cytokine failed to increase
the population of monocytes in CCR2−/− and APPSwe/PS1/
CCR2−/− mice (Figure 9).
DISCUSSION
Immune system is a key feature in AD pathology, but its role
has yet to be fully unraveled. Here, we have analyzed monocyte
subset frequency associated to age-dependent amyloid patho-
logical progression in APPSwe/PS1 mice. The main findings are
the reduced levels of monocytes, due to the decreased frequency
of CX3CR1lowLy6-ChighGr1+CCR2+ subset in bloodstream and
bone marrow of 6-month-old APPSwe/PS1 mice. This defect in
monocyte levels corresponds to the onset ofmemory impairment,
synaptic disruption, down-regulation of neuroprotective factor,
and an enhanced accumulation of soluble Aβ in hippocampus.
While density and area of Aβ plaques do not closely cor-
respond to the degree of dementia, increased levels of soluble
Aβ seem more closely associated with cognitive decline in AD
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FIGURE 5 | Monocyte levels are drastically diminished in 6-month-old
APPSwe/PS1 mice. Circulating monocyte numbers were determined by
FACS analysis within the population of leukocytes (CD45+ ) in the blood of
WT and APPSwe/PS1 mice at 5 weeks and 6 months of age. Monocytes
were characterized by CD11b and CD115 expression and were quantified
within the population of CD45+ cells. At 5 weeks of age, WT and
APPSwe/PS1 mice exhibited similar levels of monocytes (A and C). In
contrast, APPSwe/PS1 mice had fewer monocytes than WT mice at 6
months of age (B and C). Results are expressed as the Mean ± SEM;
n = 7–8; Student’s t-test; ∗p < 0.05; ∗ vs. WT at the same age.
(Lue et al., 1999; McLean et al., 1999; Naslund et al., 2000;
Lesné et al., 2006, 2008; Cheng et al., 2007). As we previ-
ously observed in others mouse models of AD (Richard et al.,
2008; Naert and Rivest, 2011a, 2012), neither onset nor inten-
sity of the memory decline correlated with the senile plaques
at all ages studied in APPSwe/PS1 mice. A significant increase
of intra- and extracellular pools of Aβ was found in hippocam-
pus of 6-month-old APPSwe/PS1 mice. This increase occurred
concomitantly with the apparition of mnesic impairments and
the deficit of synaptic markers. Soluble Aβ was detected before
plaque formation, synaptic impairments, neurotrophin deficits,
and memory decline (at 3 months of age). In the Tg2576 model,
memory impairment begins 6 months before plaque formation
when Aβ dimers start to accumulate (Kawarabayashi et al., 2004).
Indeed soluble Aβ can induce cognitive impairment (Larson and
Lesné, 2011), such as extracellular Aβ*56 (Lesné et al., 2006)
or soluble Aβ dimer and trimer (Cleary et al., 2005; Shankar
et al., 2008). In AD patients, soluble intracellular and membrane-
associated Aβ in temporal neocortex is more closely related to
AD symptoms than other Aβ species (Steinerman et al., 2008).
Increased levels of intraneuronal Aβ aggravated the mnesic deficit
in APPSwe/PS1/CCR2−/− mice (Naert and Rivest, 2011a), sug-
gesting that accumulation of soluble intraneuronal Aβ is a key
feature for the synaptic pathology in AD.
Synaptic plasticity is involved in learning and memory, and
requires the expression of proteins able to mediate changes
necessary for the increase in synaptic strength and memory.
Alterations in synapses appear to be among the earliest events
in the initiation of the cognitive decline that characterize AD
and have long been considered the best pathological corre-
lates of cognitive decline in AD (Coleman and Yao, 2003).
Correlations between alterations in BDNF expression and/or
function and mechanisms occurring in AD are well established
(Connor et al., 1997; Tapia-Arancibia et al., 2008). Here we
also observed a strong decrease of BDNF mRNA in hippocam-
pus of 6-month-old APPSwe/PS1 mice. At the same time the
different isoforms of its specific receptors, TrkB—TrkB FL, T1,
and T2—are all down-regulated. Expression of BDNF is signif-
icantly reduced in AD and mildly cognitively impaired patients
(Tapia-Arancibia et al., 2008). Recently, impaired TrkB recep-
tor signaling was reported to contribute to memory impair-
ments in APPSwe/PS1 dE9 mice (Kemppainen et al., 2012).
The BDNF gene delivered into amyloid-transgenic mice was
found to reverse synapse loss, resulting in partial recovery
of synaptic markers, and restoration of learning and memory
(Nagahara et al., 2009).
In addition the immediate early genes Arc and Egr1, which are
clearly involved in learning and memory processes in hippocam-
pus, were drastically reduced in 6-month-old APPSwe/PS1 mice.
Subunits of ionotropic glutamate receptors, NMDA (NR2A and
NR2B) and AMPA (AMPA1), and PSD95 were also significantly
decreased in the hippocampus of these mice. Overexpression of
the NR2B subunit leads to improved memory function (Tang
et al., 1999), whereas hippocampal injection of antisense oligonu-
cleotides directed against NR2B mRNA inhibits cognitive func-
tions (Clayton et al., 2002). These molecules (e.g., AMPA1
and PSD-95) are critical for synaptic plasticity (Malinow and
Malenka, 2002). PSD-95 is involved in recruiting and holding
glutamate receptors at the surface (Xiao et al., 1998; Ango et al.,
2000) and Arc expression is also closely related to NMDA activ-
ity (Bloomer et al., 2008). BDNF stimulates Arc expression in
neurons by a mechanism that involves the TrkB receptor and
is also dependent on the NMDA glutamate receptor (Yin et al.,
2002). BDNF plays a key role in regulating expression and synap-
tic delivery of AMPA receptor subunits (Li andKeifer, 2009) and it
regulates the synaptic localization of PSD95 via a TrkB-dependent
mechanism (Yoshii et al., 2011) and enhances AMPA trafficking to
cell membrane (Li and Keifer, 2009).
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FIGURE 6 | Defective production of Gr1+Ly6-ChighCCR2+ monocytes in
6-month-old APPSwe/PS1 mice. Gr1+Ly6-ChighCCR2+ monocytes were
quantified by FACS analysis in the blood of WT and APPSwe/PS1 mice at 5
weeks and 6 months of age. Monocytes were determined by the presence of
CD11b and CD115. Different subsets of monocytes were characterized using
Gr1, Ly6-C, and CCR2 antibodies. At 5 weeks of age, WT and APPSwe/PS1
mice exhibited similar levels of Gr1+ (A and C) and Gr1− monocytes (A and
D). A marked increase in the population of Gr1+ monocytes was found in the
bloodstream of 6-month-old WT mice, but this phenomenon was totally
prevented in APPSwe/PS1 mice (B and C). Although these mice failed to
exhibit such increase in Gr1+ monocytes, they had similar number of blood
Gr1− monocytes when compared to WT animals (B and D). The low
frequency of Gr1+Ly6-ChighCCR2+ monocytes was confirmed in 6-month-old
APPSwe/PS1 mice using more specific markers of the Gr1+ monocyte (e.g.,
Ly6-C and CCR2) (E–H). Results are expressed as the Mean ± SEM; n = 7–8;
Student’s t-test; ∗p < 0.05; ∗ vs. WT at the same age.
Down-regulated expression of these genes has a clear impact
on synaptic plasticity processes underlying long-term potentia-
tion and memory in AD. This decrease of synaptic genes can
be explained by the accumulation of soluble Aβ since hip-
pocampus of 6-month-old APPSwe/PS1 mice had elevated lev-
els of both extracellular and intracellular Aβ. Both intra- and
extracellular Aβ has the ability to affect expression of learning
related genes (Wegenast-Braun et al., 2009). A decline in Arc
and Egr1 expression levels was correlated with the occurrence
of cognitive impairment during aging (Blalock et al., 2003) and
in transgenic mice carrying genes responsible for AD (Dickey
et al., 2003, 2004). Aβ oligomers can inhibit BDNF-induced
Arc expression in culture cortical neurons (Wang et al., 2006;
Echeverria et al., 2007), an effect modulated NMDA activity
(Shankar et al., 2007). Because these genes are well-known to
interact together, their low expression levels together with Aβ
accumulation may explain the progressive cognitive decline of
APPSwe/PS1 mice.
This accumulation of soluble Aβ could result of an enhanced
production, a reduced degradation and/or a disrupted clearance.
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FIGURE 7 | Gr1+Ly6-ChighCCR2+ monocyte frequency is diminished in
the bone marrow of 6-month-old APPSwe/PS1 mice. Leukocytes and
Gr1+Ly6-ChighCCR2+ monocytes were quantified by FACS analysis in the
bone marrow of WT and APPSwe/PS1 mice at 6 months of age. The
leukocyte population was assessed using the CD45 marker. At 6 months of
age, WT and APPSwe/PS1 mice exhibited similar levels of leukocytes (A).
In the population of CD45+ cells, the inflammatory monocytes were
determined by the presence of CD11b and high expression levels of
Ly6-C. A marked decrease in the population of Ly6-Chigh monocytes was
found in the bone marrow of 6-month-old APPSwe/PS1 mice (B). Results
are expressed as the Mean ± SEM; n = 6–7; Student’s t-test; ∗p < 0.05;
∗ vs. WT.
A major phenomenon in AD is the inability of mononuclear
phagocytes to clear Aβ. Indeed, transplantation of competent
CCR2 hematopoietic stem cells is able to counteract amy-
loid pathology and to restore mnesic capacity in 6-month-old
APPSwe/PS1 and APPSwe/PS1/CCR2−/− mice (Naert and Rivest,
2012). In addition, CCR2 gene delivery in cells of the bone mar-
row restored the memory and learning capacities of 6-month-old
APPSwe/PS1 mice (Naert and Rivest, 2012), suggesting strongly
that there is dysfunctional CCR2 system in the bone marrow
of APPSwe/PS1 mice. For the first time we demonstrated that
6-month-old APPSwe/PS1 mice exhibited in the bloodstream a
significant reduction of monocyte frequency, resulting of mono-
cytopenia in the CX3CR1lowLy6-ChighGr1+CCR2+ subset. As we
have previously observed at the age of 3–4 months (Michaud
et al., 2011; Naert and Rivest, 2012), 5-week-old WT and
APPSwe/PS1 mice exhibited similar monocyte frequency for both
subsets. In addition, the CX3CR1highLy6-ClowGr1−CCR2− sub-
set has similar frequency in 6-month-old APPSwe/PS1 mice than
in 6-month-old WT mice and this at all ages studied (Michaud
et al., 2011; Naert and Rivest, 2012). As we only observed an
effect in one of the two-monocyte subsets and not in the whole
monocyte population, a proper effect of the presence of APP
transgene controlled by the prion promoter seems to be excluded,
suggesting strongly a preferential effect of Aβ on inflammatory
monocytes.
Therefore, this reduced level of inflammatory monocytes
in bloodstream seems to be CCR2-dependent and could be
explained by a reduced egress of monocyte from the bone mar-
row to blood circulation. Indeed, one major function of CCR2 is
to permit the migration of CCR2+ monocytes from bone mar-
row to the blood (Serbina and Pamer, 2006; Engel et al., 2008). In
addition CCR2 mediates hematopoietic stem and progenitor cell
trafficking to sites of inflammation andmonocyte infiltration into
brain (Izikson et al., 2000; Babcock et al., 2003; Si et al., 2010).
As the ratio of Gr1+/Gr1− monocytes is significantly decreased
in a context of AD, less CX3CR1lowLy6-ChighGr1+CCR2+ mono-
cytes are available to clear Aβ in the bloodstream but also to
be recruited into brain to remove brain Aβ. This expansion of
the non-classical CD14+CD16+ subtype—counterpart of mouse
CX3CR1highLy6-ClowGr1−CCR2−—has been already observed in
aged healthy adult (Seidler et al., 2010). In addition their pheno-
type changes dependent on age, resulting in lower expression of
activation markers and chemokine receptors (Seidler et al., 2010).
The CD14++CD16− monocytes display some variation in CCR2
expression, with highest levels in healthy adults at the age between
30 and 50 years and a significant decreased expression in adults
older than 50 years (Seidler et al., 2010). Although alterations
in peripheral immune cells are also reported in patients with
AD, examination of peripheral leukocytes—principally lympho-
cytes and monocytes—by different groups revealed conflicting
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FIGURE 8 | Short M-CSF treatment is able to prevent and to rescue
learning and memory impairment in APPSwe/PS1 mice. APPSwe/PS1
mice received M-CSF treatment during 4 days (40μg/Kg/day) before (at
3 months) or after occurrence of mnesic deficit (at 6 months) and were
tested in the T water-maze paradigm 3 months later (A). The numbers of
trials (B and E) and the latency (C and F) to accomplish the task were
determined during reversal learning phase. M-CSF treatment prevented
spatial memory decline generally observed in 6-month-old APPSwe/PS1
mice (B). In addition, M-CSF treatment after occurrence of mnesic
impairment (at 6 months) (D) rescued spatial memory in 9-month-old
APPSwe/PS1 mice (E). Results are expressed as the Mean ± SEM;
n = 8–16 per group; ∗p < 0.05 and ∗∗∗p < 0.001; ∗ vs. WT,  vs.
APPSwe/PS1 mice. (One-way ANOVA was performed in each genotype
using Bonferroni or Tamhane’s post-hoc test).
results and currently there is no general consensus on the mod-
ifications of leukocytes in AD patients. By contrast, a recent
analysis of peripheral blood mononuclear cell (PBMC) in a large
older human population revealed increased of CCR2 levels asso-
ciated with lower Mini Mental State Examination (MMSE) scores
(Harries et al., 2012). These data corroborates the increased CCR2
expression in PBMC of AD patients (Reale et al., 2008; Pellicano
et al., 2010). It is important to mention that CCR2 expression
levels were only determined in lymphocytes (Reale et al., 2008;
Pellicano et al., 2010). CCR2 expression is globally upregulated
in CD4+ lymphocytes and down regulated in CD8+ lympho-
cytes (Reale et al., 2008). Unfortunately these studies have not
investigated the CCR2 status in monocytes of AD patients neither
that they did perform the distribution of each monocyte subset.
The global increase of CCR2 expression levels in PBMC could
then reflect CCR2 upregulation in lymphocyte, considering the
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FIGURE 9 | Short M-CSF treatment increases monocyte frequency in
WT and APPSwe/PS1 mice in a CCR2-dependent manner. Monocyte
frequency was determined by FACS analysis within the population of CD45+
cells using the CD11b and CD115 markers in WT, CCR2−/−, APPSwe/PS1, and
APPSwe/PS1/CCR2−/− mice. Mice received saline or M-CSF treatment during
4 days (40μg/Kg/day) at the age of 4 months and blood samples were
analyzed 24 h after the last injection. M-CSF treatment increased the
frequency of monocytes (CD11b+CD115+ ) in both WT and APPSwe/PS1
groups of mice. In contrast, monocyte frequency remained very low in
CCR2−/− and APPSwe/PS1/CCR2−/− mice treated or not with the cytokine.
Results are expressed as the Mean ± SEM; n = 5–8; Student’s t-test;
∗p < 0.05; ∗∗p < 0.01; ∗ vs. saline treatment in the same genotype.
prevalence of lymphocytes in human PBMC. More work has to
be done to better understand the role of CCR2 in monocytic cells
in AD patients.
Here analysis of CCR2 levels in FACS studies did not reveal a
different intensity in monocytes between 6-month-old WT and
APPSwe/PS1 mice (data not shown), suggesting that their low
blood frequencies may be caused by a decreased production or
their retention in bone marrow as observed in CCR2-deficient
mice (Serbina and Pamer, 2006). We found a decreased frequency
of Ly6-Chigh monocytes in the bone marrow of 6-month-old
APPSwe/PS1 mice, suggesting a deficient production of Ly6-
Chigh monocytes. These data support the concept that alteration
in the numbers, phenotype, and functionality of mononuclear
cells occurred in AD. Indeed monocytes of AD patients exhibit
poor in vitro differentiation, poor phagocytic properties for and
undergo apoptosis after Aβ application (Fiala et al., 2005).
The development of blood monocytes is dependent onM-CSF
(also known as Csf-1) (Auffray et al., 2009). In mice deficient
in M-CSF and its receptor M-CSFR (CD115), monocyte fre-
quency is drastically reduced in bloodstream (Ryan et al., 2001;
Dai et al., 2002). M-CSF transgene expression rescues the dif-
ferentiation of monocytes in M-CSF-deficient mice (Ryan et al.,
2001). It is very interesting to note that a short systemic treat-
ment with M-CSF was able to prevent and rescue cognitive
impairments in APPSwe/PS1 mice and reestablish the circulating
level of monocytes. The defect in mononuclear cells observed in
APPSwe/PS1 mice is therefore not dependent on CD115, since
M-CSF treatment increased monocyte frequency in 4-month-old
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APPSwe/PS1 mice in levels comparable to those of age-matched
WT mice. M-CSF treatment failed to increase monocyte popula-
tion in CCR2−/− and APPSwe/PS1/CCR2−/− mice, suggesting a
CCR2-dependent mechanism of M-CSF. These data suggest that
expression of CCR2 is low in the bone marrow of APPSwe/PS1
mice or Ly6-Chigh monocyte differentiation is impaired, and
this may explain the low frequency of inflammatory mono-
cytes, but these cells still have the ability to respond in pres-
ence of hematopoietic cytokines. These data obtained after 4-day
M-CSF treatment confirm our previous results observed after
a long M-CSF treatment in APPSwe/PS1 mice (Boissonneault
et al., 2009). Indeed a long M-CSF treatment prevented and
restored cognitive deficits, but M-CSF also increased the num-
ber of microglia and decreased the number of Aβ deposits
(Boissonneault et al., 2009), certainly by enhancing Aβ phago-
cytosis by microglia, a known effect of M-CSF (Mitrasinovic
and Murphy, 2003; Mitrasinovic et al., 2003; Majumdar et al.,
2007). Besides, other hematopoietic cytokines, such as G-CSF
or GM-CSF, had been shown to have beneficial effects in AD
mouse model (Tsai et al., 2007; Volmar et al., 2008; Sanchez-
Ramos et al., 2009; Boyd et al., 2010; Jiang et al., 2010; Li et al.,
2011). More interestingly, G-CSF decreased both brainAβ deposi-
tion and soluble Aβ accumulation by activating directly microglia
and by enhancing the recruitment of BMDM and also restored
synaptophysin expression in APP mice (Sanchez-Ramos et al.,
2009). Despite a general beneficial therapeutic effect of most of
hematopoietic cytokines, M-CSF seems to be a preferential target
in AD as M-CSF acts specifically on bone marrow to produce the
monocytes, the microglial precursor cells. Although APPSwe/PS1
mice exhibited with aging a significant monocytopenia, their
bone marrow cells are still able to respond properly to M-CSF
treatment, suggesting a functional CSF1-R. Monocyte develop-
ment and differentiation (Auffray et al., 2009) and Ly6-Chigh
monocyte extravasation (Tagliani et al., 2011) are dependent on
M-CSF.
A defect in the monocytopoiesis was found in a mouse
model of AD, resulting in a decrease of CX3CR1lowLy6-
ChighGr1+CCR2+ subset of monocytes. This phenomenon may
be a keymechansism for the accumulation of Aβ, synaptic disrup-
tion, deficit in neurotrophic factors, and decline of memory and
learning functions. Stimulating the production of CCR2+ mono-
cytes withM-CSF should be seriously considered for clinical trials
in early diagnosed AD patients.
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